查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128077

癌症疫苗市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測。

Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

癌症疫苗市場成長要素

全球癌症疫苗市場預計到2025年將達到116.2億美元，從2026年的127.1億美元成長到2034年的453.7億美元，預測期內複合年成長率（CAGR）將達到17.25%。北美地區將引領全球市場，預計到2025年將佔38.3%的市場佔有率，這主要得益於其先進的醫療基礎設施、活性化的癌症研究以及個人化免疫療法的快速普及。

癌症疫苗包括預防性疫苗（可降低子宮頸癌等病毒相關癌症的風險）和治療性疫苗（可刺激免疫系統識別並摧毀癌細胞）。在全球癌症負擔日益加重以及mRNA平台、新抗原發現、腫瘤定序和精準醫療等領域的進步推動下，癌症疫苗市場正在迅速擴張。製藥公司正大力投資研發，力求推出創新疫苗，在改善治療效果的同時降低復發率。

癌症疫苗市場趨勢

改變市場格局的關鍵趨勢之一是人工智慧 (AI) 和生物資訊學在識別腫瘤特異性抗原方面的應用日益廣泛。 AI 平台使研究人員能夠更快地分析基因組和免疫反應數據，有助於開發更有效的個人化癌症疫苗。此外，繼 mRNA 疫苗技術取得成功之後，製造商正在擴大針對每位患者腫瘤特異性突變的個人化癌症疫苗的研究。生技公司和製藥公司之間日益密切的合作正在推動整體和治療性疫苗研發的進一步創新。

市場促進因素

癌症疫苗市場成長的關鍵促進因素之一是治療性疫苗與免疫查核點抑制劑聯合應用的日益普及。合併免疫療法能夠增強免疫系統辨識和清除癌細胞的能力，同時降低疾病復發的風險。全球癌症發生率的上升、 人類乳突病毒(HPV)疫苗和B型肝炎疫苗接種計劃的擴大、政府的支持措施以及個人化癌症治療的持續進步，都使得已開發國家和新興國家醫療保健市場對癌症疫苗的需求強勁。

市場限制因素

儘管取得了令人鼓舞的進展，但仍有許多因素限制著市場成長。治療性癌症疫苗在證明其對不同癌症類型具有一致的臨床療效方面常常面臨挑戰。漫長的研發週期、高昂的臨床試驗成本、複雜的法規核准流程以及高昂的生產成本進一步阻礙了其商業化進程。此外，個人化疫苗需要進行腫瘤定序和客製化生產，這導致治療費用高昂，且在低收入地區難以取得。

市場機遇

對個人化新抗原疫苗的加大投入，為未來市場擴張提供了最具前景的機會之一。基因測序、人工智慧驅動的抗原預測以及mRNA技術的進步，正助力企業開發針對個別患者量身定做的高度標靶化疫苗。製藥公司、生技公司和研究機構之間日益密切的合作，可望加速疫苗的商業化進程。新興國家免疫規劃的擴展以及人們對癌症預防意識的不斷提高，也將創造長期的成長機會。

市場區隔

從類型來看，市場可分為預防性疫苗和治療性疫苗。預計到2025年，由於人類乳突病毒(HPV)疫苗和B型肝炎疫苗透過國家免疫規劃廣泛分發，預防性疫苗市場將佔主導地位。同時，隨著個人化免疫療法的臨床應用日益廣泛，治療性疫苗市場預計將實現最快成長。

依技術分類，疫苗市場包括分子疫苗、載體疫苗和細胞疫苗。由於DNA、RNA、胜肽和蛋白質疫苗技術的快速發展，分子疫苗已佔最大市場佔有率。

從指標來看，子宮頸癌仍然是最大的癌症發生率類別，這主要得益於人類乳突病毒(HPV)疫苗計劃在全球範圍內的成功。肺癌預計將成為成長最快的癌症，這主要歸功於個人化免疫療法臨床研究的擴展。

就分銷管道而言，由於患者數量的增加、先進癌症治療設施的發展以及癌症疫苗可及性的提高，醫院在市場中佔主導地位。

區域展望

到2025年，北美將以44.5億美元的市場規模引領全球癌症疫苗市場。強大的研究基礎設施、個人化醫療的快速普及、高額的醫療保健支出以及積極的臨床試驗將繼續鞏固該地區的主導地位。美國仍是最大的貢獻者，這主要得益於其在免疫腫瘤學和基於mRNA的癌症疫苗研發領域不斷加大投入。

歐洲擁有全球第二大市場規模，這得益於政府主導的疫苗接種舉措、不斷擴大的癌症研究以及旨在預防癌症的公共衛生計畫的加強。德國和英國等國持續投資先進的疫苗研發和個人化醫療。

預計亞太地區在預測期內將實現顯著成長，主要促進因素包括癌症發生率上升、醫療基礎設施不斷改善、免疫意識增強以及政府對生物技術創新的支持。中國、日本和印度正在疫苗生產和癌症研究領域進行大量投資。

在拉丁美洲、中東和非洲，隨著各國政府加強免疫接種計劃、改善醫療保健服務以及增加對癌症篩檢和預防措施的投資，市場正在逐步擴大。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
  • 市場趨勢

第4章：主要考慮因素

  • 主要國家各種癌症的盛行率（2025 年）
  • 主要國家和地區監管狀況概述
  • 管道分析，主要公司
  • 產業重大發展：合併、收購與合作。
  • 新產品發布
  • 產品與收入分佈圖：全球癌症疫苗市場

第5章：2021-2034年全球癌症疫苗市場分析、洞察與預測

  • 市場分析、洞察與預測：按類型
    • 為了預防
    • 治療
  • 市場分析、洞察與預測：按技術分類
    • 基於分子
    • 基於向量
    • 基於細胞
  • 市場分析、洞察與預測：按指標
    • 子宮頸癌
    • 膀胱癌
    • 攝護腺癌
    • 肺癌
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院
    • 政府和組織提供的物資
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美癌症疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲癌症疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 德國
    • 其他歐洲國家

第8章：亞太地區癌症疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲癌症疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲癌症疫苗市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Dendreon Pharmaceuticals LLC.
    • Serum Institute of India Pvt. Ltd.
    • Merck & Co., Inc.
    • GSK plc
    • Walvax Biotechnology Co., Ltd.
    • Synthaverse SA
    • Center of Molecular Immunology
    • Moderna, Inc.
    • Wantai BioPharm
    • BioNTech SE
Product Code: FBI106958

Growth Factors of cancer vaccines Market

The global cancer vaccines market was valued at USD 11.62 billion in 2025 and is expected to grow from USD 12.71 billion in 2026 to USD 45.37 billion by 2034, registering a CAGR of 17.25% during the forecast period. North America dominated the global market with a 38.3% market share in 2025, supported by advanced healthcare infrastructure, increasing cancer research, and rapid adoption of personalized immunotherapy.

Cancer vaccines include both preventive vaccines, which reduce the risk of virus-associated cancers such as cervical cancer, and therapeutic vaccines, which stimulate the immune system to recognize and destroy cancer cells. The growing global burden of cancer, combined with technological advancements in mRNA platforms, neoantigen discovery, tumor sequencing, and precision medicine, is accelerating market expansion. Pharmaceutical companies are investing heavily in research and development to introduce innovative vaccines that improve treatment outcomes while reducing recurrence rates.

Cancer Vaccines Market Trends

One of the major trends transforming the market is the growing use of artificial intelligence (AI) and bioinformatics for identifying tumor-specific antigens. AI-powered platforms enable researchers to analyze genomic and immune-response data faster, helping develop personalized cancer vaccines with improved effectiveness. In addition, the success of mRNA vaccine technology has encouraged manufacturers to expand research into individualized cancer vaccines that target unique mutations in each patient's tumor. Increasing collaboration between biotechnology firms and pharmaceutical companies is further driving innovation across preventive and therapeutic vaccine development.

Market Drivers

The primary factor driving the cancer vaccines market growth is the increasing adoption of therapeutic vaccines alongside immune checkpoint inhibitors. Combination immunotherapy improves the immune system's ability to recognize and eliminate cancer cells while reducing the chances of disease recurrence. Rising global cancer incidence, expanding immunization programs for HPV and Hepatitis B vaccines, favorable government initiatives, and continuous advancements in personalized oncology are creating strong demand for cancer vaccines across developed and emerging healthcare markets.

Market Restraints

Despite promising developments, several factors continue to limit market growth. Therapeutic cancer vaccines often face challenges in demonstrating consistent clinical effectiveness across different cancer types. Long development timelines, expensive clinical trials, complex regulatory approvals, and high manufacturing costs further restrict commercialization. Personalized vaccines also require tumor sequencing and customized production, making treatment more expensive and limiting accessibility in lower-income regions.

Market Opportunities

Growing investment in personalized neoantigen vaccines presents one of the strongest opportunities for future market expansion. Improvements in genomic sequencing, AI-driven antigen prediction, and mRNA technology are enabling companies to develop highly targeted vaccines for individual patients. Increasing collaborations between pharmaceutical companies, biotechnology firms, and research institutions are expected to accelerate commercialization. Expanding vaccination programs in emerging countries and greater awareness regarding cancer prevention will also create long-term growth opportunities.

Market Segmentation

Based on type, the market is segmented into preventive and therapeutic vaccines. The preventive segment dominated the market in 2025 due to the widespread use of HPV and Hepatitis B vaccines through national immunization programs. Meanwhile, the therapeutic segment is projected to witness the fastest growth as personalized immunotherapy gains wider clinical acceptance.

By technology, the market includes molecular-based, vector-based, and cell-based vaccines. Molecular-based vaccines accounted for the largest share because of rapid advancements in DNA, RNA, peptide, and protein-based vaccine technologies.

Based on indication, cervical cancer remained the leading segment owing to the global success of HPV vaccination programs. Lung cancer is expected to experience the fastest growth due to expanding clinical research in personalized immunotherapy.

By distribution channel, hospitals dominated the market because of increasing patient visits, advanced oncology care facilities, and higher availability of cancer vaccines.

Regional Outlook

North America led the global cancer vaccines market in 2025 with a valuation of USD 4.45 billion. Strong research infrastructure, rapid adoption of personalized medicine, high healthcare spending, and active clinical trials continue to support regional leadership. The U.S. remains the largest contributor due to increasing investment in immuno-oncology and mRNA-based cancer vaccine development.

Europe represents the second-largest market, supported by government-backed vaccination initiatives, growing oncology research, and expanding public health programs aimed at cancer prevention. Countries such as Germany and the U.K. continue investing in advanced vaccine research and personalized therapies.

Asia Pacific is expected to witness substantial growth throughout the forecast period due to increasing cancer incidence, expanding healthcare infrastructure, rising awareness regarding preventive vaccination, and government support for biotechnology innovation. China, Japan, and India are investing heavily in vaccine manufacturing and cancer research.

Latin America and the Middle East & Africa are also experiencing gradual market expansion as governments strengthen immunization programs, improve healthcare access, and increase investments in cancer screening and prevention initiatives.

Competitive Landscape

The cancer vaccines market is highly competitive, with leading companies focusing on research collaborations, product innovation, clinical trials, and strategic partnerships. Major players include Dendreon Pharmaceuticals LLC., Serum Institute of India Pvt. Ltd., Merck & Co., Inc., GSK plc, Moderna, Inc., BioNTech SE, Walvax Biotechnology Co., Ltd., Synthaverse S.A., Center of Molecular Immunology, and Wantai BioPharm. These companies continue investing in mRNA technology, personalized vaccine development, and next-generation immunotherapy platforms to strengthen their global market position.

Recent industry developments highlight the market's innovation pace. In 2026, Anixa Biosciences partnered with Cytovance Biologics to manufacture clinical materials for its breast cancer vaccine. During 2025, several companies expanded HPV vaccine accessibility, introduced new personalized vaccine candidates, and strengthened collaborations aimed at accelerating cancer prevention and treatment.

Conclusion

The global cancer vaccines market is entering a period of rapid expansion as healthcare systems increasingly prioritize cancer prevention, precision medicine, and personalized immunotherapy. Valued at USD 11.62 billion in 2025, the market is projected to reach USD 12.71 billion in 2026 and USD 45.37 billion by 2034, driven by continuous technological advancements, expanding immunization programs, increasing research investments, and growing adoption of innovative therapeutic cancer vaccines worldwide.

Segmentation By Type, Technology, Indication, Distribution Channel, and Region

By Type * Preventive

  • Therapeutic

By Technology * Molecular-based

  • Vector-based
  • Cell-based

By Indication * Cervical Cancer

  • Bladder Cancer
  • Prostate Cancer
  • Lung Cancer
  • Others

By Distribution Channel * Hospitals

  • Government & Organization Supply
  • Others

By Region *

  • North America (By Type, By Technology, By Indication, By Distribution Channel, By Country)
    • U.S.
    • Canada
  • Europe (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-Region)
    • France
    • Italy
    • Spain
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, By Technology, By Indication, By Distribution Channel, By Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Challenges
  • 3.5. Market Trends

4. Key Insights

  • 4.1. Prevalence of Different Cancers, by Key Countries, 2025
  • 4.2. Overview of Regulatory Scenario by Key Countries/Regions
  • 4.3. Pipeline Analysis, Key Players
  • 4.4. Key Industry Developments - Mergers, Acquisitions & Partnerships
  • 4.5. New Product Launches
  • 4.6. Product & Revenue Mapping: Global Cancer Vaccines Market

5. Global Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Preventive
    • 5.1.2. Therapeutic
  • 5.2. Market Analysis, Insights and Forecast - By Technology
    • 5.2.1. Molecular-based
    • 5.2.2. Vector-based
    • 5.2.3. Cell-based
  • 5.3. Market Analysis, Insights and Forecast - By Indication
    • 5.3.1. Cervical Cancer
    • 5.3.2. Bladder Cancer
    • 5.3.3. Prostate Cancer
    • 5.3.4. Lung Cancer
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospitals
    • 5.4.2. Government & Organization Supply
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Preventive
    • 6.1.2. Therapeutic
  • 6.2. Market Analysis, Insights and Forecast - By Technology
    • 6.2.1. Molecular-based
    • 6.2.2. Vector-based
    • 6.2.3. Cell-based
  • 6.3. Market Analysis, Insights and Forecast - By Indication
    • 6.3.1. Cervical Cancer
    • 6.3.2. Bladder Cancer
    • 6.3.3. Prostate Cancer
    • 6.3.4. Lung Cancer
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospitals
    • 6.4.2. Government & Organization Supply
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Preventive
    • 7.1.2. Therapeutic
  • 7.2. Market Analysis, Insights and Forecast - By Technology
    • 7.2.1. Molecular-based
    • 7.2.2. Vector-based
    • 7.2.3. Cell-based
  • 7.3. Market Analysis, Insights and Forecast - By Indication
    • 7.3.1. Cervical Cancer
    • 7.3.2. Bladder Cancer
    • 7.3.3. Prostate Cancer
    • 7.3.4. Lung Cancer
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospitals
    • 7.4.2. Government & Organization Supply
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. France
    • 7.5.2. Italy
    • 7.5.3. Spain
    • 7.5.4. U.K.
    • 7.5.5. Germany
    • 7.5.6. Rest of Europe

8. Asia Pacific Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Preventive
    • 8.1.2. Therapeutic
  • 8.2. Market Analysis, Insights and Forecast - By Technology
    • 8.2.1. Molecular-based
    • 8.2.2. Vector-based
    • 8.2.3. Cell-based
  • 8.3. Market Analysis, Insights and Forecast - By Indication
    • 8.3.1. Cervical Cancer
    • 8.3.2. Bladder Cancer
    • 8.3.3. Prostate Cancer
    • 8.3.4. Lung Cancer
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospitals
    • 8.4.2. Government & Organization Supply
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Preventive
    • 9.1.2. Therapeutic
  • 9.2. Market Analysis, Insights and Forecast - By Technology
    • 9.2.1. Molecular-based
    • 9.2.2. Vector-based
    • 9.2.3. Cell-based
  • 9.3. Market Analysis, Insights and Forecast - By Indication
    • 9.3.1. Cervical Cancer
    • 9.3.2. Bladder Cancer
    • 9.3.3. Prostate Cancer
    • 9.3.4. Lung Cancer
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospitals
    • 9.4.2. Government & Organization Supply
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Preventive
    • 10.1.2. Therapeutic
  • 10.2. Market Analysis, Insights and Forecast - By Technology
    • 10.2.1. Molecular-based
    • 10.2.2. Vector-based
    • 10.2.3. Cell-based
  • 10.3. Market Analysis, Insights and Forecast - By Indication
    • 10.3.1. Cervical Cancer
    • 10.3.2. Bladder Cancer
    • 10.3.3. Prostate Cancer
    • 10.3.4. Lung Cancer
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospitals
    • 10.4.2. Government & Organization Supply
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Dendreon Pharmaceuticals LLC.
    • 11.2.2. Serum Institute of India Pvt. Ltd.
    • 11.2.3. Merck & Co., Inc.
    • 11.2.4. GSK plc
    • 11.2.5. Walvax Biotechnology Co., Ltd.
    • 11.2.6. Synthaverse S.A.
    • 11.2.7. Center of Molecular Immunology
    • 11.2.8. Moderna, Inc.
    • 11.2.9. Wantai BioPharm
    • 11.2.10. BioNTech SE

List of Tables

  • Table 1: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 3: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication 2021-2034
  • Table 4: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Cancer Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 7: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 8: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication 2021-2034
  • Table 9: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Cancer Vaccines Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 11: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 12: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 13: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication 2021-2034
  • Table 14: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Cancer Vaccines Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 17: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 18: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication 2021-2034
  • Table 19: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Cancer Vaccines Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 21: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 23: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication 2021-2034
  • Table 24: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Cancer Vaccines Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 27: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 28: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Indication 2021-2034
  • Table 29: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Cancer Vaccines Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cancer Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cancer Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Cancer Vaccines Market Value Share (%), by Technology, 2025 & 2034
  • Figure 4: Global Cancer Vaccines Market Value Share (%), by Indication, 2025 & 2034
  • Figure 5: Global Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Cancer Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 8: North America Cancer Vaccines Market Value Share (%), by Type, 2025
  • Figure 9: North America Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 10: North America Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 11: North America Cancer Vaccines Market Value (USD billion), by Indication 2025 & 2034
  • Figure 12: North America Cancer Vaccines Market Value Share (%), by Indication 2025
  • Figure 13: North America Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Cancer Vaccines Market Value (USD billion), by Country, 2025 & 2034
  • Figure 16: North America Cancer Vaccines Market Value Share (%), by Country, 2025
  • Figure 17: Europe Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 18: Europe Cancer Vaccines Market Value Share (%), by Type, 2025
  • Figure 19: Europe Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 20: Europe Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 21: Europe Cancer Vaccines Market Value (USD billion), by Indication 2025 & 2034
  • Figure 22: Europe Cancer Vaccines Market Value Share (%), by Indication 2025
  • Figure 23: Europe Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Cancer Vaccines Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Cancer Vaccines Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 28: Asia Pacific Cancer Vaccines Market Value Share (%), by Type, 2025
  • Figure 29: Asia Pacific Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 30: Asia Pacific Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 31: Asia Pacific Cancer Vaccines Market Value (USD billion), by Indication 2025 & 2034
  • Figure 32: Asia Pacific Cancer Vaccines Market Value Share (%), by Indication 2025
  • Figure 33: Asia Pacific Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Cancer Vaccines Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Cancer Vaccines Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Latin America Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 38: Latin America Cancer Vaccines Market Value Share (%), by Type, 2025
  • Figure 39: Latin America Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 40: Latin America Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 41: Latin America Cancer Vaccines Market Value (USD billion), by Indication 2025 & 2034
  • Figure 42: Latin America Cancer Vaccines Market Value Share (%), by Indication 2025
  • Figure 43: Latin America Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Cancer Vaccines Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Cancer Vaccines Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Cancer Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 48: Middle East & Africa Cancer Vaccines Market Value Share (%), by Type, 2025
  • Figure 49: Middle East & Africa Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 50: Middle East & Africa Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 51: Middle East & Africa Cancer Vaccines Market Value (USD billion), by Indication 2025 & 2034
  • Figure 52: Middle East & Africa Cancer Vaccines Market Value Share (%), by Indication 2025
  • Figure 53: Middle East & Africa Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Cancer Vaccines Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Cancer Vaccines Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 57: Global Cancer Vaccines Market Share (%), by Company, 2025